5-(2-fluorophenyl)-1-(pyridin-3-ylsulfonyl)-1H-pyrrole-3-carbonitrile

‌Vonoprazan Fumarate Intermediate 2 (CAS 881677-11-8) | High-Purity Building Block for Gastric Drug API Synthesis‌
‌Google Search Keywords‌: Vonoprazan Fumarate Intermediate 2, CAS 881677-11-8, Vonoprazan Synthesis Material, P-CAB Intermediate, Gastric Drug API Precursor

🔬 ‌Product Overview‌
Vonoprazan Fumarate Intermediate 2 (CAS 881677-11-8) is a critical chemical component in the synthesis of ‌Vonoprazan Fumarate‌, a next-generation potassium-competitive acid blocker (P-CAB) used to treat gastric acid-related disorders like gastroesophageal reflux disease (GERD) and peptic ulcers. This intermediate ensures efficient and high-yield production of Vonoprazan Fumarate API, meeting stringent pharmaceutical quality requirements.
‌Primary Function‌: Enables scalable and impurity-controlled synthesis of Vonoprazan Fumarate API.
‌Applications‌: Gastrointestinal drug manufacturing, generic P-CAB development, clinical research.

✅ ‌Key Advantages‌
⭐ ‌Ultra-High Purity‌

• Purity ≥99% (HPLC/LC-MS validated), minimizing unwanted byproducts and ensuring API quality.

⚙️ ‌Optimized Process Efficiency‌

• Reduces synthesis time by 15-25% through streamlined reaction pathways, enhancing cost-effectiveness.

🌡️ ‌Enhanced Stability‌

• Stable at controlled room temperature (15-25°C), suitable for global logistics and extended storage.

📜 ‌Regulatory Readiness‌

• Manufactured under ‌ICH Q7‌ and ‌GMP‌ guidelines, compliant with USP/EP standards for intermediates.

📋 ‌Applications‌

• ‌API Production‌: Key precursor in Vonoprazan Fumarate API synthesis for acid suppression therapies.

• ‌Generic Drug Formulations‌: Supports cost-effective alternatives to branded P-CAB medications.

• ‌Digestive Health R&D‌: Used to study novel P-CAB derivatives with improved pharmacokinetics.

• ‌Clinical Trial Materials‌: Critical for scaling up batches during pre-clinical and Phase I-III trials.

🏅 ‌Quality Certifications‌

1. Rigorously tested via ‌HPLC, GC, NMR, and Mass Spectrometry‌ (USP/EP/ICH compliant).

2. Comprehensive Certificate of Analysis (CoA) with impurity profiles, spectral data, and chromatograms.

🌐 ‌Market Trends‌
The global gastric acid-related drug market is projected to grow at ‌6.8% CAGR (2024-2030)‌, driven by rising GERD prevalence and demand for potent P-CABs like Vonoprazan. Intermediate suppliers are crucial to meeting production needs, especially in Asia-Pacific markets where generic approvals are accelerating.

🔍 ‌Why Choose Us?‌

• ‌Custom Synthesis‌: Tailored purity grades (98%-99.9%) and batch sizes (mg to kg scale).

• ‌Fast Delivery‌: Temperature-controlled shipping with real-time tracking and regulatory documentation.

• ‌Technical Expertise‌: End-to-end support for API synthesis, impurity control, and regulatory filings.